Top Markets
#1 COTI COTI +38.86%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +32.35%
#3 Fabric Protocol Fabric Protocol +30.24%
#4 GALA GALA +30.05%
#5 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +29.48%
#6 Bitcoin Cash Bitcoin Cash +29.01%
#7 Tutorial Tutorial +28.70%
#8 Talus Network Talus Network +25.87%
#9 Zora Zora +24.18%
#10 Magma Finance Magma Finance +24.04%
Coin of the day
COTI COTI
Settings
Language
ENGLISH
Currency
USD
Theme
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Rank in Stocks #24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Share Price
$0.78611575
Market Cap
$60.45M
Change (1 day)
0.00%
Change (1 year)
-12.06%
Country
NO
Trade Lytix Biopharma AS (LYTIX)

Category

Healthcare
P/E ratio for Lytix Biopharma AS (LYTIX)
P/E ratio as of 2026 TTM: 0
According to Lytix Biopharma AS latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Lytix Biopharma AS from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.